Paper Details

  1. Home
  2. Paper Details

Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives.

Author: ChaeHee Bok, ParkSeon Mee, YounSei Jin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discussed the current and future landscape of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, highlighting the challenges of viral resistance and the promising potential of oral drug combinations for achieving sustained virological response (SVR).
Paper Details　
Original Abstract of the Article :
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687480/

データ提供：米国国立医学図書館（NLM）

Direct-Acting Antivirals: A New Dawn in the Desert of Hepatitis C

This study delves into the exciting world of [antiviral therapy and infectious diseases] and explores the development of new drugs to treat chronic hepatitis C, a debilitating disease that affects millions worldwide. The researchers focus on direct-acting antivirals (DAAs), a new class of drugs that directly target the hepatitis C virus. These drugs are changing the landscape of hepatitis C treatment, offering more effective and convenient options. The study highlights the progress made in developing new DAAs, including those that can be taken orally and are more effective against resistant strains of the virus.

A Triple Threat: Fighting Hepatitis C with a Caravan of Drugs

The study shows how combinations of DAAs, like a caravan traveling together for strength, can be highly effective in treating hepatitis C. The researchers are optimistic that these new drug combinations, such as sofosbuvir and daclatasvir plus asunaprevir, hold great promise for achieving high cure rates.

Hope on the Horizon: A New Oasis in the Desert of Hepatitis C

This research offers hope for patients with chronic hepatitis C, highlighting the ongoing development of new and effective treatment options. It's like discovering a new oasis in the desert, bringing relief and the possibility of a healthy future.

Dr.Camel's Conclusion

This study is a testament to the power of scientific innovation in the fight against infectious diseases. It's a reminder that with persistent research and development, we can overcome even the most formidable challenges.

Date :
  1. Date Completed 2013-09-30
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23844410

DOI: Digital Object Identifier

PMC3687480

Related Literature

Article Analysis
・Side Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.